JP6374414B2 - 多孔質担体粒子および微粒子化薬物の呼吸用凝集体 - Google Patents

多孔質担体粒子および微粒子化薬物の呼吸用凝集体 Download PDF

Info

Publication number
JP6374414B2
JP6374414B2 JP2015562509A JP2015562509A JP6374414B2 JP 6374414 B2 JP6374414 B2 JP 6374414B2 JP 2015562509 A JP2015562509 A JP 2015562509A JP 2015562509 A JP2015562509 A JP 2015562509A JP 6374414 B2 JP6374414 B2 JP 6374414B2
Authority
JP
Japan
Prior art keywords
particles
dry powder
pharmaceutically acceptable
indacaterol
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015562509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512494A (ja
JP2016512494A5 (enExample
Inventor
ハートマン，ミシェル
タララ，トーマス
テウグ，パトリック
ウィールズ，ジェフェリー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016512494A publication Critical patent/JP2016512494A/ja
Publication of JP2016512494A5 publication Critical patent/JP2016512494A5/ja
Application granted granted Critical
Publication of JP6374414B2 publication Critical patent/JP6374414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015562509A 2013-03-14 2014-03-13 多孔質担体粒子および微粒子化薬物の呼吸用凝集体 Active JP6374414B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
US61/784,842 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (3)

Publication Number Publication Date
JP2016512494A JP2016512494A (ja) 2016-04-28
JP2016512494A5 JP2016512494A5 (enExample) 2017-04-13
JP6374414B2 true JP6374414B2 (ja) 2018-08-15

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562509A Active JP6374414B2 (ja) 2013-03-14 2014-03-13 多孔質担体粒子および微粒子化薬物の呼吸用凝集体

Country Status (22)

Country Link
US (2) US9452139B2 (enExample)
EP (1) EP2968570A1 (enExample)
JP (1) JP6374414B2 (enExample)
KR (1) KR20150129716A (enExample)
CN (1) CN105188757B (enExample)
AU (2) AU2014229265A1 (enExample)
BR (1) BR112015021814A2 (enExample)
CA (1) CA2905615A1 (enExample)
CL (1) CL2015002632A1 (enExample)
EA (1) EA201591729A1 (enExample)
GT (1) GT201500295A (enExample)
HK (1) HK1212616A1 (enExample)
IL (1) IL240963A (enExample)
MA (1) MA38397A1 (enExample)
MX (1) MX2015012814A (enExample)
PE (1) PE20151655A1 (enExample)
PH (1) PH12015501882A1 (enExample)
SA (1) SA515361055B1 (enExample)
SG (1) SG11201506397QA (enExample)
TN (1) TN2015000395A1 (enExample)
WO (1) WO2014141135A1 (enExample)
ZA (1) ZA201505768B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
JP2016506947A (ja) * 2013-01-31 2016-03-07 プロソニックス リミテッド 吸入療法において使用するのに適する多成分結晶粒子を含む医薬組成物
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
KR20160137543A (ko) * 2014-03-27 2016-11-30 노파르티스 아게 활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN114206137A (zh) * 2019-08-15 2022-03-18 雅培制药有限公司 使用微粉化的营养粉末制造方法和粉末组合物
BR112022020732A2 (pt) * 2020-04-13 2022-12-20 Univ Basel Método de dosagem e tratamento de pacientes com um psicodélico, método para determinar uma dose de um psicodélico para um indivíduo, método para definir doses terapêuticas de um psicodélico em ensaios clínicos, método para tratar afecções psiquiátricas em um indivíduo, métodos de terapia, e método para monitorar indivíduos para depressão após tratamento com lsd
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
TW202237102A (zh) * 2020-12-11 2022-10-01 大陸商江蘇恒瑞醫藥股份有限公司 用於肺部遞送的藥物組合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
US12534460B2 (en) 2021-04-30 2026-01-27 Mind Medicine, Inc. LSD salt crystal forms
IL310569A (en) 2021-08-19 2024-03-01 Mind Medicine Inc IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
WO2025256638A1 (zh) * 2024-06-14 2025-12-18 上海济昀生物科技有限公司 一种混悬型三联吸入气雾剂组合物及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
EP0057401B1 (en) 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
ATE137675T1 (de) 1991-06-26 1996-05-15 Schering Corp Inhalator für medikamente in pulverform
KR0163472B1 (ko) 1992-12-18 1998-11-16 에릭 에스. 딕커 분말 약품용 흡입기
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PL187750B1 (pl) 1994-09-21 2004-09-30 Nektar Therapeutics Sposób i urządzenie do wytwarzania aerozolu ze sproszkowanego leku
DE69617754T2 (de) 1996-01-03 2002-08-08 Glaxo Group Ltd., Greenford Inhalator
CZ298885B6 (cs) 1996-02-21 2008-03-05 Schering Corporation Inhalátor práškových léku
PT1371645E (pt) 1996-11-11 2013-05-21 Meda Pharma Gmbh & Co Kg Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
PT1131059E (pt) 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2265944T3 (es) 1999-05-28 2007-03-01 Nektar Therapeutics Aparato y procedimiento para aerosolizar una composicion farmaceutica en polvo.
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AU2003287132B2 (en) 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
PL1610850T3 (pl) 2003-04-09 2012-11-30 Novartis Ag Urządzenie rozpylające z osłoną wlotu powietrza
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
AU2005216061B2 (en) 2004-02-24 2010-05-27 Microdose Therapeutx, Inc. Synthetic jet based medicament delivery method and apparatus
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
SI2044025T1 (sl) 2006-06-30 2013-01-31 Novartis Ag Kinolinonski derivati in njihovi farmacevtski sestavki
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CA2667225C (en) 2006-10-25 2015-06-09 Novartis Ag Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
KR101621986B1 (ko) 2008-05-15 2016-05-17 노파르티스 아게 플루오로퀴놀론의 폐 전달
ES2617680T3 (es) 2009-04-09 2017-06-19 Novartis Ag Proceso para la preparación de sales de pirrolidinio
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PH12012501792A1 (en) 2010-04-01 2012-12-10 Chiesi Farm Spa Process for preparing carrier particles for dry powders for inhalation
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
US20160354388A1 (en) 2016-12-08
SG11201506397QA (en) 2015-09-29
EP2968570A1 (en) 2016-01-20
IL240963A0 (en) 2015-11-30
JP2016512494A (ja) 2016-04-28
BR112015021814A2 (pt) 2017-07-18
PE20151655A1 (es) 2015-11-26
AU2014229265A1 (en) 2015-09-03
CN105188757A (zh) 2015-12-23
CN105188757B (zh) 2019-04-30
HK1212616A1 (zh) 2016-06-17
US20140302147A1 (en) 2014-10-09
AU2017203258B2 (en) 2019-06-20
EA201591729A1 (ru) 2016-05-31
TN2015000395A1 (en) 2017-01-03
US9452139B2 (en) 2016-09-27
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31
SA515361055B1 (ar) 2016-11-13
CL2015002632A1 (es) 2016-03-28
ZA201505768B (en) 2017-03-29
US9744178B2 (en) 2017-08-29
PH12015501882A1 (en) 2015-12-07
WO2014141135A1 (en) 2014-09-18
MX2015012814A (es) 2016-02-03
IL240963A (en) 2017-05-29
CA2905615A1 (en) 2014-09-18
AU2017203258A1 (en) 2017-06-08
GT201500295A (es) 2017-09-28

Similar Documents

Publication Publication Date Title
JP6374414B2 (ja) 多孔質担体粒子および微粒子化薬物の呼吸用凝集体
JP6082049B2 (ja) 閉塞性または炎症性気道疾患を治療するための２種以上の活性成分を含有する粒子の乾燥粉末製剤
JP6232079B2 (ja) スプレーブレンディングによるスプレー乾燥製剤の脱アモルファス化
JP2016519160A (ja) ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
JP7712916B2 (ja) 吸入用乾燥粉末製剤のための新規担体粒子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170310

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180719

R150 Certificate of patent or registration of utility model

Ref document number: 6374414

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250